Highlights from the 7th Cachexia Conference: Muscle wasting pathophysiological detection and novel treatment strategies

Nicole Ebner, Lisa Steinbeck, Wolfram Doehner, Stefan D. Anker, Stephan von Haehling

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

This article highlights preclinical and clinical studies in the field of wasting disorders that were presented at the 7th Cachexia Conference held in Kobe, Japan, in December 2013. This year, the main topics were the development of new methods and new biomarkers in the field of cachexia and wasting disorders with particular focus on inflammatory pathways, growth differentiation factor-15, myostatin, the ubiquitin proteasome-dependent pathway, valosin and the regulation of ubiquitin-specific protease 19 that is involved in the differentiation of myogenin and myosin heavy chain. This article presents highlights from the development of drugs that have shown potential in the treatment of wasting disorders, particularly the ghrelin receptor agonist anamorelin, the myostatin antagonist REGN1033, the selective androgen receptor modulators enobosarm and TEI-E0001, and the anabolic catabolic transforming agent espindolol. In addition, novel data on the prevalence and detection methods of muscle wasting/sarcopenia are presented, including the D3-creatine dilution method and several new biomarkers.

Original languageEnglish
Pages (from-to)27-34
Number of pages8
JournalJournal of Cachexia, Sarcopenia and Muscle
Volume5
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Cachexia
Myostatin
Muscles
Growth Differentiation Factor 15
Biomarkers
Ubiquitin-Specific Proteases
Ghrelin Receptor
Myogenin
Sarcopenia
Myosin Heavy Chains
Creatine
Androgen Receptors
Proteasome Endopeptidase Complex
Ubiquitin
Japan
Pharmaceutical Preparations

Keywords

  • Cachexia
  • Muscle wasting
  • Sarcopenia
  • Therapy

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Physiology (medical)

Cite this

Highlights from the 7th Cachexia Conference : Muscle wasting pathophysiological detection and novel treatment strategies. / Ebner, Nicole; Steinbeck, Lisa; Doehner, Wolfram; Anker, Stefan D.; von Haehling, Stephan.

In: Journal of Cachexia, Sarcopenia and Muscle, Vol. 5, No. 1, 2014, p. 27-34.

Research output: Contribution to journalArticle

Ebner, Nicole ; Steinbeck, Lisa ; Doehner, Wolfram ; Anker, Stefan D. ; von Haehling, Stephan. / Highlights from the 7th Cachexia Conference : Muscle wasting pathophysiological detection and novel treatment strategies. In: Journal of Cachexia, Sarcopenia and Muscle. 2014 ; Vol. 5, No. 1. pp. 27-34.
@article{7622e8a44bed49aa8323cdd6235ad03e,
title = "Highlights from the 7th Cachexia Conference: Muscle wasting pathophysiological detection and novel treatment strategies",
abstract = "This article highlights preclinical and clinical studies in the field of wasting disorders that were presented at the 7th Cachexia Conference held in Kobe, Japan, in December 2013. This year, the main topics were the development of new methods and new biomarkers in the field of cachexia and wasting disorders with particular focus on inflammatory pathways, growth differentiation factor-15, myostatin, the ubiquitin proteasome-dependent pathway, valosin and the regulation of ubiquitin-specific protease 19 that is involved in the differentiation of myogenin and myosin heavy chain. This article presents highlights from the development of drugs that have shown potential in the treatment of wasting disorders, particularly the ghrelin receptor agonist anamorelin, the myostatin antagonist REGN1033, the selective androgen receptor modulators enobosarm and TEI-E0001, and the anabolic catabolic transforming agent espindolol. In addition, novel data on the prevalence and detection methods of muscle wasting/sarcopenia are presented, including the D3-creatine dilution method and several new biomarkers.",
keywords = "Cachexia, Muscle wasting, Sarcopenia, Therapy",
author = "Nicole Ebner and Lisa Steinbeck and Wolfram Doehner and Anker, {Stefan D.} and {von Haehling}, Stephan",
year = "2014",
doi = "10.1007/s13539-014-0136-z",
language = "English",
volume = "5",
pages = "27--34",
journal = "Journal of Cachexia, Sarcopenia and Muscle",
issn = "2190-5991",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Highlights from the 7th Cachexia Conference

T2 - Muscle wasting pathophysiological detection and novel treatment strategies

AU - Ebner, Nicole

AU - Steinbeck, Lisa

AU - Doehner, Wolfram

AU - Anker, Stefan D.

AU - von Haehling, Stephan

PY - 2014

Y1 - 2014

N2 - This article highlights preclinical and clinical studies in the field of wasting disorders that were presented at the 7th Cachexia Conference held in Kobe, Japan, in December 2013. This year, the main topics were the development of new methods and new biomarkers in the field of cachexia and wasting disorders with particular focus on inflammatory pathways, growth differentiation factor-15, myostatin, the ubiquitin proteasome-dependent pathway, valosin and the regulation of ubiquitin-specific protease 19 that is involved in the differentiation of myogenin and myosin heavy chain. This article presents highlights from the development of drugs that have shown potential in the treatment of wasting disorders, particularly the ghrelin receptor agonist anamorelin, the myostatin antagonist REGN1033, the selective androgen receptor modulators enobosarm and TEI-E0001, and the anabolic catabolic transforming agent espindolol. In addition, novel data on the prevalence and detection methods of muscle wasting/sarcopenia are presented, including the D3-creatine dilution method and several new biomarkers.

AB - This article highlights preclinical and clinical studies in the field of wasting disorders that were presented at the 7th Cachexia Conference held in Kobe, Japan, in December 2013. This year, the main topics were the development of new methods and new biomarkers in the field of cachexia and wasting disorders with particular focus on inflammatory pathways, growth differentiation factor-15, myostatin, the ubiquitin proteasome-dependent pathway, valosin and the regulation of ubiquitin-specific protease 19 that is involved in the differentiation of myogenin and myosin heavy chain. This article presents highlights from the development of drugs that have shown potential in the treatment of wasting disorders, particularly the ghrelin receptor agonist anamorelin, the myostatin antagonist REGN1033, the selective androgen receptor modulators enobosarm and TEI-E0001, and the anabolic catabolic transforming agent espindolol. In addition, novel data on the prevalence and detection methods of muscle wasting/sarcopenia are presented, including the D3-creatine dilution method and several new biomarkers.

KW - Cachexia

KW - Muscle wasting

KW - Sarcopenia

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84896397419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896397419&partnerID=8YFLogxK

U2 - 10.1007/s13539-014-0136-z

DO - 10.1007/s13539-014-0136-z

M3 - Article

AN - SCOPUS:84896397419

VL - 5

SP - 27

EP - 34

JO - Journal of Cachexia, Sarcopenia and Muscle

JF - Journal of Cachexia, Sarcopenia and Muscle

SN - 2190-5991

IS - 1

ER -